Multaq is a medication often prescribed for the treatment of atrial fibrillation or atrial flutter (irregular heart rhythms). It comes in tablet form and is usually taken twice a day. Clinical studies have shown that the product is useful for preventing heart-related hospitalizations and can help delay the recurrence of irregular heart rhythms. Potential side effects include nausea, diarrhea, and general weakness.
What Is Multaq?
Multaq® (dronedarone) is a prescription medication approved to treat irregular heart rhythms known as atrial fibrillation or atrial flutter. It is chemically related to amiodarone (an older arrhythmia medication) but is easier to dose and appears to be less likely to cause certain dangerous side effects, compared to amiodarone.
(Click Multaq Uses for more information on what the medication is used for, including possible off-label uses.)
Who Makes Multaq?
This medication is made by Sanofi Winthrop Industries for sanofi-aventis U.S. LLC.
How Does Multaq Work?
It is not yet clear exactly how Multaq works to treat arrhythmias. Most arrhythmia medications are classified using the Vaughn-Williams classification system, which divides arrhythmia medications into four classes depending on how they work. At this point, it seems that Multaq has activity that belongs to all four of the classes.
Effects of Multaq
This medication has been thoroughly studied in various different clinical trials. In general, these studies showed that Multaq was more effective than a placebo (a "sugar pill" with no active ingredients) for preventing heart-related hospitalizations. Some studies also showed that this medication could delay the time until the first recurrence of atrial fibrillation or atrial flutter.
Written by/reviewed by: Kristi Monson, PharmD;Arthur Schoenstadt, MD
Last reviewed by: KristiMonson, PharmD;
List of references (click here):
Multaq [package insert]. Bridgewater, NJ: sanofi-aventis U.S. LLC;2012 September.
Sanofi-Aventis. DIONYSOS study results showed the respective profiles of dronedarone and amiodarone (12/23/2008). Sanofi-aventis Web site. Available at: http://en.sanofi-aventis.com/binaries/20081223_dionysos_fe_en_en_tcm28-23624.pdf. Accessed July 10, 2009.
Food and Drug Administration, Center for Drug Evaluation and Research. Electronic orange book: approved drug products with therapeutic equivalence evaluations. FDA Web site. Available at: http://www.fda.gov/cder/ob/. Accessed August 9, 2012.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click